Last reviewed · How we verify
ALK HDM AIT 12 DU
ALK HDM AIT 12 DU is an allergen immunotherapy (AIT) vaccine that desensitizes the immune system to house dust mite (HDM) allergens through repeated subcutaneous administration.
ALK HDM AIT 12 DU is an allergen immunotherapy (AIT) vaccine that desensitizes the immune system to house dust mite (HDM) allergens through repeated subcutaneous administration. Used for House dust mite allergic rhinitis and/or asthma.
At a glance
| Generic name | ALK HDM AIT 12 DU |
|---|---|
| Sponsor | ALK-Abelló A/S |
| Drug class | Allergen immunotherapy vaccine |
| Target | House dust mite allergens (Der p 1, Der p 2, and other HDM proteins) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Allergy |
| Phase | Phase 3 |
Mechanism of action
This is an allergy immunotherapy product designed to induce immune tolerance to house dust mite allergens by gradually exposing patients to increasing doses of HDM extract. The therapy works by shifting the immune response from IgE-mediated (allergic) to IgG-mediated (protective) antibodies and promoting regulatory T cell responses, thereby reducing allergic symptoms upon natural allergen exposure.
Approved indications
- House dust mite allergic rhinitis and/or asthma
Common side effects
- Local injection site reactions (erythema, swelling, pruritus)
- Systemic allergic reactions
- Itching or swelling of mouth/throat
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |